2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2579

Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis
Abstract Number: 2580

Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients
Abstract Number: 2581

Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis
Abstract Number: 2582

N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis
Abstract Number: 2583

Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Abstract Number: 2584

Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
Abstract Number: 2585

Serum MMP-3 and OPG As Predictors of Response to Traditional Dmards in a Treatment NaïVe Early Rheumatoid Arthritis Cohort
Abstract Number: 2586

Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial
Abstract Number: 2587

The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Abstract Number: 2588

The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Abstract Number: 2589

Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Abstract Number: 2590

The Efficacy of Additional Immunoadsorption on the Modulation of Disease Activity in Patients with Severe Rheumatoid Arthritis
Abstract Number: 2591

Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 2592

The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink
Abstract Number: 2593

The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].